Recurrence and cancer‐specific death after adjuvant chemotherapy for Stage III colon cancer

The recommended standard of care for patients after resection of Stage III colon cancer is adjuvant 5‐fluorouracil based chemotherapy – FOLFOX (fluorouracil, leucovorin with oxaliplatin) – or CAPOX (capecitabine, oxaliplatin). This may be modified in older patients or depending on comorbidity. This has been challenged recently as the apparent benefit of adjuvant chemotherapy may arise from improvements in surgery or preoperative imaging or pathology staging. This study compares recurrence and colon‐cancer‐specific death between patients who received postoperative adjuvant chemotherapy and those who did not.

[1]  Shan Wang,et al.  Is it time to define complete mesocolic excision as a standardized colon cancer surgery? , 2018, Translational gastroenterology and hepatology.

[2]  S. Clemenceau,et al.  Surgical technique , 2018, Neurophysiologie Clinique.

[3]  O. Dent,et al.  Long‐term results following an anatomically based surgical technique for resection of colon cancer: a comparison with results from complete mesocolic excision , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[4]  L. Påhlman,et al.  Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Church,et al.  Primacy of surgery for colorectal cancer , 2015, The British journal of surgery.

[6]  O. Dent,et al.  Complications after resection of colorectal cancer in a public hospital and a private hospital , 2015, ANZ journal of surgery.

[7]  J. E. Jansen,et al.  Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. , 2015, The Lancet. Oncology.

[8]  D. Winter,et al.  Complete mesocolic resection and extended lymphadenectomy for colon cancer: a systematic review , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[9]  N. Haboubi.  Colonic surgery for cancer: a new paradigm , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[10]  K. Matzel,et al.  Standardized surgery for colonic cancer: complete mesocolic excision and central ligation – technical notes and outcome , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[11]  B. Vonen,et al.  Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group , 2009, Acta oncologica.

[12]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[13]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[14]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[15]  H. Grönberg,et al.  Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group , 2005, Acta oncologica.

[16]  M. Kohli,et al.  Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. , 2004, Journal of the National Cancer Institute.

[17]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[18]  D. Lowy,et al.  Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles , 2004 .

[19]  O. Dent,et al.  Adverse histopathological findings as a guide to patient management after curative resection of node‐positive colonic cancer , 2004, The British journal of surgery.

[20]  Marc Buyse,et al.  Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  O. Dent,et al.  Surgical Technique and Survival in Patients Having a Curative Resection for Colon Cancer , 2003, Diseases of the colon and rectum.

[22]  A. Piga,et al.  The Role of Levamisole in the Adjuvant Treatment of Stage III Colon Cancer Patients: A Randomized Trial of 5-Fluorouracil and Levamisole Versus 5-Fluorouracil Alone , 2003, Cancer investigation.

[23]  T. Wiggers,et al.  Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III , 2001, British Journal of Cancer.

[24]  R. Porschen,et al.  Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Plukker,et al.  The addition of low-dose leucovorin to the combination of 5-fluorouracillevamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer , 2000 .

[27]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[28]  H. Rockette,et al.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[30]  W. Scheithauer,et al.  Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. , 1995, European journal of cancer.

[31]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[32]  T. Reynolds.  Dutch trial casts doubt on colorectal adjuvant therapy. , 1995, Journal of the National Cancer Institute.

[33]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[34]  Marco Lorenzi,et al.  Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. , 1994, Gastroenterology.

[35]  J. Habrand,et al.  No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Krischer,et al.  Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[38]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  N. Petrelli,et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Chapuis,et al.  The prognostic value of substaging colorectal carcinoma. A prospective study of 1117 cases with standardized pathology , 1987, Cancer.

[41]  R C Newland,et al.  Terminology and classification of colorectal adenocarcinoma: the Australian clinico-pathological staging system. , 1983, The Australian and New Zealand journal of surgery.

[42]  P. Chapuis,et al.  The relationship of survival to staging and grading of colorectal carcinoma: A prospective study of 503 cases , 1981, Cancer.

[43]  M. Orditura,et al.  Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study , 2013, International Journal of Colorectal Disease.

[44]  N. Wolmark,et al.  Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. , 2004, Journal of the National Cancer Institute.

[45]  R. Scott,et al.  Long-Term Results , 2001 .

[46]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  K. Tiver,et al.  Should patients with Dukes' C colon cancer receive adjuvant chemotherapy after curative resection? , 1991, The Australian and New Zealand journal of surgery.

[48]  Adjuvant therapy for patients with colon and rectum cancer. , 1990, Consensus statement. National Institutes of Health Consensus Development Conference.